The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $34.18

Today's change+0.64 +1.91%
Updated March 27 4:01 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $34.18

Today's change+0.64 +1.91%
Updated March 27 4:01 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S crosses above 20-day moving average

Novo Nordisk A/S closed up sharply Monday, rallying (U.S.)$0.64 or 1.91% to (U.S.)$34.18 and crossing above its 20-day moving average. Although unchanged over the last five days, shares are down 4.68% for the last year to date. This security has underperformed the S&P 500 by 51.21% during the last year.

Key company metrics

  • Open(U.S.) $33.89
  • Previous close(U.S.) $33.54
  • High(U.S.) $34.28
  • Low(U.S.) $33.77
  • Bid / Ask-- / --
  • YTD % change-4.68%
  • Volume1,708,739
  • Average volume (10-day)1,767,313
  • Average volume (1-month)2,323,988
  • Average volume (3-month)2,885,131
  • 52-week range(U.S.) $30.89 to (U.S.) $57.81
  • Beta0.73
  • Trailing P/E15.74×
  • P/E 1 year forward15.64×
  • Forward PEG1.63×
  • Indicated annual dividend(U.S.) $1.33
  • Dividend yield3.88%
  • Trailing EPS(U.S.) $2.17
Updated March 27 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+33.93%

Based on its net profit margin of 33.93%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.41%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue29,57227,53727,45927,212
Total other revenue--------
Total revenue29,57227,53727,45927,212
Gross profit24,65423,55123,41422,978
Total cost of revenue4,9183,9864,0454,234
Total operating expense18,36615,11714,96214,903
Selling / general / administrative9,0757,8757,7407,649
Research & development4,4703,4583,3313,304
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--000
Other operating expenses, total-97-202-154-284
Operating income11,20612,42012,49712,309
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax10,94212,30112,60211,953
Income after tax8,6999,8039,9689,455
Income tax, total2,2432,4982,6342,498
Net income8,6999,8039,9689,455
Total adjustments to net income--------
Net income before extra. items8,6999,8039,9689,455
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items8,6999,8039,9689,455
Inc. avail. to common incl. extra. items8,6999,8039,9689,455
Diluted net income8,6999,8039,9689,455
Dilution adjustment0--00
Diluted weighted average shares2,5172,5312,5412,550
Diluted EPS excluding extraordinary itemsvalue per share3.463.873.923.71
Dividends per sharevalue per share6.770.000.000.00
Diluted normalized EPSvalue per share3.463.873.923.71